NEW YORK (360Dx) – Quanterix said after the close of the market on Monday that it is collaborating with OncoGenesis to develop a test for cervical disease.
The companies will develop the protein biomarker-based test using Quanterix's forthcoming SP-X Imaging and Analysis system, and OncoGenesis will handle test commercialization. Called CerMark, the test will measure protein markers linked to high-risk HPV infection and cervical disease progression.
Boston-based OncoGenesis is targeting the test at women in resource-constrained settings as an alternative to cytology-based tests like Pap smears.
"We are very excited by the potential of this diagnostic test to offer women in the developing world access to an ease-of-use, cost-effective way of monitoring cervical disease,” Kevin Hrusovsky, CEO, president and chairman of Lexington, Massachusetts-based Quanterix, said in a statement. "This represents our first step toward a diagnostic test since recently reestablishing unrestricted rights to our Simoa technology for in vitro diagnostics, and we are very pleased OncoGenesis selected one of our platforms to develop this test."
Financial and other terms of the agreement were not disclosed.